Open Payments

The Stamford Hospital

Type
Teaching hospital
Where
STAMFORD, CT
Medicare CCN
070006
Received
$650,066 in 74 records, 2024 ($53,756 general, $596,309 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment28$53,756
2024Research payment46$596,309

By company

CompanyRecordsAmountYears
PFIZER INC.17$347,9112024
Novartis Pharmaceuticals Corporation2$97,4842024
E.R. Squibb & Sons, L.L.C.4$73,4192024
Sumitomo Pharma America, Inc.14$63,5492024
Siemens Medical Solutions USA, Inc.1$17,2832024
Stryker Corporation4$16,7122024
Insulet Corporation11$9,9252024
Genentech, Inc.5$7,9712024
Celgene Corporation3$5,8952024
AstraZeneca Pharmaceuticals LP1$3,0002024
ABBVIE INC.1$2,9872024
Tandem Diabetes Care, Inc.7$2,2502024
bioMerieux Inc1$5862024
Haemonetics Corporation1$5002024
CSL Behring1$5002024
Eli Lilly and Company1$912024

By nature of payment

NatureRecordsAmount
Research payment46$596,309
Grant2$20,283
Debt forgiveness4$17,163
Compensation for services other than consulting, including serving as faculty or as a speaker at a v18$12,175
Space rental or facility fees (teaching hospital only)2$3,500
Education1$500
Long term medical supply or device loan1$135

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31Stryker Corporation$16,231Debt forgivenessCash or cash equivalent2024
2024-12-31PFIZER INC.$9,845Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2024
2024-12-31Stryker Corporation$174Debt forgivenessCash or cash equivalent2024
2024-12-31Stryker Corporation$171Debt forgivenessCash or cash equivalent2024
2024-12-31Stryker Corporation$135Long term medical supply or device loanIn-kind items and servicesSPY Device, ENDOSCOPY2024
2024-12-19PFIZER INC.$20,305Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2024
2024-12-13E.R. Squibb & Sons, L.L.C.$981Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Study - Breast Cancer HR Pos / HER2 Neg Neo adjuvant2024
2024-12-12Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-12-05Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-11-26PFIZER INC.$12,550Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2024
2024-11-20Insulet Corporation$1,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-11-06Sumitomo Pharma America, Inc.$17,877Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2024
2024-11-06Novartis Pharmaceuticals Corporation$2,799Research paymentIn-kind items and servicesA Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety an2024
2024-11-06Celgene Corporation$2,000Research paymentCash or cash equivalentCelgene Connect Myeloid Disease Registry2024
2024-11-06Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-10-24Haemonetics Corporation$500EducationCash or cash equivalentTEG6S HEMOSTASIS SYSTEM Device, DEVICES2024
2024-10-21CSL Behring$500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-10-17Genentech, Inc.$1,635Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2024
2024-10-16Insulet Corporation$1,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-10-09PFIZER INC.$11,082Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2024
2024-10-03ABBVIE INC.$2,987Research paymentCash or cash equivalentRINVOQ Biological, IMMUNOLOGYA Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Part2024
2024-10-02Insulet Corporation$375Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-09-30bioMerieux Inc$586Debt forgivenessCash or cash equivalent2024
2024-09-28PFIZER INC.$12,921Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2024
2024-09-25Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-09-20Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-09-11Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-09-05E.R. Squibb & Sons, L.L.C.$1,895Research paymentCash or cash equivalentConnect MM The Multiple Myeloma Disease Registry2024
2024-08-20Genentech, Inc.$985Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2024
2024-08-15E.R. Squibb & Sons, L.L.C.$3,000GrantCash or cash equivalent2024
2024-08-13E.R. Squibb & Sons, L.L.C.$67,543Research paymentCash or cash equivalentA Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibr2024
2024-07-31Sumitomo Pharma America, Inc.$15,883Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2024
2024-07-31Sumitomo Pharma America, Inc.$410Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2024
2024-07-31Sumitomo Pharma America, Inc.$410Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2024
2024-07-31Sumitomo Pharma America, Inc.$410Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2024
2024-07-31Sumitomo Pharma America, Inc.$410Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2024
2024-07-31Sumitomo Pharma America, Inc.$410Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2024
2024-07-26Insulet Corporation$1,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-06-26PFIZER INC.$21,442Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2024
2024-06-08PFIZER INC.$27,104Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2024
2024-06-06Genentech, Inc.$1,709Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2024
2024-05-29Sumitomo Pharma America, Inc.$7,105Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2024
2024-05-29Tandem Diabetes Care, Inc.$175Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-05-22Insulet Corporation$800Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-05-22Tandem Diabetes Care, Inc.$175Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-05-21PFIZER INC.$44,020Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2024
2024-05-16Celgene Corporation$1,895Research paymentCash or cash equivalentConnect MM- The Multiple Myeloma Disease Registry2024
2024-05-16Insulet Corporation$1,600Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-05-02PFIZER INC.$30,709Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2024
2024-04-17PFIZER INC.$13,353Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2024
2024-04-10PFIZER INC.$28,102Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2024
2024-04-10Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-04-08AstraZeneca Pharmaceuticals LP$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentENHERTU Biological, Oncology2024
2024-04-03PFIZER INC.$13,249Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2024
2024-04-02Insulet Corporation$800Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-03-29PFIZER INC.$31,619Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2024
2024-03-28PFIZER INC.$21,302Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2024
2024-03-19Siemens Medical Solutions USA, Inc.$17,283GrantIn-kind items and services2024
2024-03-12Genentech, Inc.$808Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2024
2024-03-08Eli Lilly and Company$91Research paymentIn-kind items and servicesA PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS V2024
2024-03-02PFIZER INC.$33,636Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2024
2024-02-21Sumitomo Pharma America, Inc.$10,215Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2024
2024-02-21Sumitomo Pharma America, Inc.$8,874Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2024
2024-02-21Sumitomo Pharma America, Inc.$1,432Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2024
2024-02-21Sumitomo Pharma America, Inc.$80Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2024
2024-02-21Sumitomo Pharma America, Inc.$15Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2024
2024-02-21Sumitomo Pharma America, Inc.$15Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2024
2024-02-08Genentech, Inc.$2,834Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2024
2024-02-08Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-02-05Insulet Corporation$1,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-01-31Celgene Corporation$2,000Research paymentCash or cash equivalentRevlimid Drug, HematologyThe purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment2024
2024-01-25Novartis Pharmaceuticals Corporation$94,685Research paymentCash or cash equivalentSCEMBLIX Drug, OncologyA Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase 2024
2024-01-25PFIZER INC.$1,105Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2024
2024-01-09PFIZER INC.$15,558Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Western Connecticut Planning RegionStamford city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Stamford, CT, county Western Connecticut Planning Region, CT, state Connecticut; placed by its city name.

MeasurePlace (city or town)
Stamford, CT
County
Western Connecticut Planning Region, CT
State
Connecticut
Population B01003137,144627,0713,624,508
Population, 2020 census P1135,470-3,605,944
Median age B0100238.441.541.1
Under 18 B0100118.4%21.8%20.2%
65 and over B0100116.2%17.4%18.5%
Households B1100155,291235,3791,434,007
Foreign born B0500231.3%23.8%15.7%
Median household income B19013$111,586$128,188$95,781
Median family income B19113$126,493$161,625$122,706
Per capita income B19301$67,068$82,266$55,915
Poverty rate B1700110.1%7.5%10.0%
Unemployment rate B230254.9%5.3%5.6%
Civilian labor force B2302581,944346,5571,959,490
Mean commute (minutes) B0801328.530.826.5
Bachelor's degree or higher B1500351.7%55.5%42.5%
Housing units B2500158,655251,5301,541,822
Owner-occupied B2500348.8%66.4%66.5%
Renters B2500351.2%33.6%33.5%
Median home value B25077$624,400$652,900$366,900
Median gross rent B25064$2,276$2,110$1,488
White, not Hispanic B0300243.2%58.6%61.9%
Black B0300217.7%9.3%9.8%
Hispanic or Latino B0300228.3%20.5%18.3%
Asian B030027.3%5.4%4.7%
American Indian and Alaska Native B030020.1%0.1%0.1%

Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); Unemployment rate: 4.7% in Sep 2016 to 5.1% in Sep 2026; low 3.1%, high 11.9% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Stamford, CT.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.